Mike P Wattjes

List of Publications by Year
in descending order

113 papers	4,721 citations	126907 33 h-index	110387 64 g-index
116 all docs	116 docs citations	116 times ranked	6600 citing authors

#	Article	IF	Citations
1	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosisâ€"establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	10.1	422
2	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain, 2019, 142, 1858-1875.	7.6	303
3	2021 MAGNIMSâ€"CMSCâ€"NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	10.2	302
4	Neuromuscular imaging in inherited muscle diseases. European Radiology, 2010, 20, 2447-2460.	4.5	289
5	The investigation of acute optic neuritis: a review and proposed protocol. Nature Reviews Neurology, 2014, 10, 447-458.	10.1	248
6	Spinal cord lesions in patients with clinically isolated syndrome. Neurology, 2013, 80, 69-75.	1.1	140
7	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	9.0	140
8	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64â€"Detector Row CT. Radiology, 2009, 253, 174-183.	7.3	121
9	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 429-435.	1.9	119
10	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	4.5	99
11	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 235-243.	1.9	89
12	The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Multiple Sclerosis Journal, 2013, 19, 1826-1840.	3.0	88
13	Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumabâ€associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2014, 76, 792-801.	5.3	82
14	Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. Multiple Sclerosis Journal, 2015, 21, 1036-1044.	3.0	78
15	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. Journal of Neurology, 2017, 264, 1155-1164.	3.6	77
16	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimerâ€™s Biomarkers in Daily Practice (ABIDE) Project. JAMA Neurology, 2017, 74, 1481.	9.0	77
17	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. Brain, 2020, 143, 2831-2843.	7.6	76
18	High field MRI in the diagnosis of multiple sclerosis: high fieldâ€"high yield?. Neuroradiology, 2009, 51, 279-292.	2.2	75

#	Article	IF	Citations
19	MRI pattern in asymptomatic natalizumab-associated PML. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 793-798.	1.9	75
20	Matrix Metalloproteinases in Alzheimerâ€™s Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
21	Differential patterns of spinal cord and brain atrophy in NMO and MS. Neurology, 2015, 84, 1465-1472.	1.1	70
22	Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Current Opinion in Neurology, 2014, 27, 260-270.	3.6	61
23	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1138-1145.	1.9	59
24	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	2.4	57
25	Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 188.	2.4	52
26	Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study. Multiple Sclerosis Journal, 2016, 22, 1154-1162.	3.0	48
27	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. Multiple Sclerosis Journal, 2014, 20, 1692-1698.	3.0	47
28	MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 879-884.	1.9	46
29	Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis. JMM Case Reports, 2016, 3, e005076.	1.3	45
30	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. Neurology, 2015, 85, 248-255.	1.1	41
31	Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach. Brain, Behavior, & Immunity - Health, 2020, 9, 100154.	2.5	41
32	Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. British Journal of Radiology, 2017, 90, 20160721.	2.2	39
33	Gray matter networks and cognitive impairment in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 382-391.	3.0	39
34	Personalized extended interval dosing of natalizumab in MS. Neurology, 2020, 95, e745-e754.	1.1	36
35	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
36	The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Multiple Sclerosis Journal, 2018, 24, 805-810.	3.0	32

#	Article	IF	Citations
37	Structural MRI. International Psychogeriatrics, 2011, 23, S13-S24.	1.0	31
38	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S299-305.	0.8	31
39	Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 535-541.	1.9	31
40	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. Journal of Neurology, 2014, 261, 1139-1143.	3.6	30
41	Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 749-754.	2.4	30
42	Personalized risk for clinical progression in cognitively normal subjectsâ€"the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
43	Recent developments in muscle imaging of neuromuscular disorders. Current Opinion in Neurology, 2016, 29, 614-620.	3.6	29
44	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. JAMA Neurology, 2018, 75, 827.	9.0	29
45	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. NeuroImage, 2017, 163, 106-114.	4.2	27
46	White Matter Hyperintensities andÂCognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. American Journal of Geriatric Psychiatry, 2014, 22, 157-166.	1.2	25
47	The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research - Neuroimaging, 2014, 222, 1-9.	1.8	25
48	Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants. Neuroimaging Clinics of North America, 2017, 27, 205-227.	1.0	25
49	Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology. Neurobiology of Aging, 2018, 71, 171-178.	3.1	25
50	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. Multiple Sclerosis Journal, 2019, 25, 352-360.	3.0	22
51	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. Multiple Sclerosis Journal, 2020, 26, 1381-1391.	3.0	22
52	Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. Multiple Sclerosis Journal, 2016, 22, 1174-1183.	3.0	21
53	The sequence of structural, functional and cognitive changes in multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102550.	2.7	21
54	Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse. Journal of Neurology, 2020, 267, 2803-2805.	3.6	20

#	Article	IF	Citations
55	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. NeuroImage: Clinical, 2021, 29, 102549.	2.7	20
56	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	19
57	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. European Radiology, 2021, 31, 5312-5323.	4.5	19
58	Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1020.	6.0	19
59	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. Journal of Alzheimer's Disease, 2015, 44, 153-162.	2.6	18
60	Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. Multiple Sclerosis Journal, 2018, 24, 1453-1460.	3.0	18
61	Imaging Patterns of Muscle Atrophy. Seminars in Musculoskeletal Radiology, 2018, 22, 299-306.	0.7	18
62	Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 44-46.	1.9	18
63	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. European Radiology, 2016, 26, 2982-2991.	4.5	17
64	Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1092-1094.	1.9	17
65	Progressive multifocal leukoencephalopathy after natalizumab discontinuation: Few and true?. Annals of Neurology, 2014, 75, 462-462.	5.3	16
66	Disease activity following pregnancy-related discontinuation of natalizumab in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e424.	6.0	15
67	Chronic cerebrospinal venous insufficiency in multiple sclerosis: the final curtain. Lancet, The, 2014, 383, 106-108.	13.7	14
68	Concomitant granule cell neuronopathy in patients with natalizumab-associated PML. Journal of Neurology, 2016, 263, 649-656.	3.6	14
69	Individual Prediction of Behavioral Variant Frontotemporal Dementia Development Using Multivariate Pattern Analysis of Magnetic Resonance Imaging Data. Journal of Alzheimer's Disease, 2019, 68, 1229-1241.	2.6	14
70	SPG7 mutations in amyotrophic lateral sclerosis: a genetic link to hereditary spastic paraplegia. Journal of Neurology, 2020, 267, 2732-2743.	3.6	14
71	Measurements of the corpus callosum index and fractional anisotropy of the corpus callosum and their cutoff values are useful to assess global brain volume loss in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 45, 102388.	2.0	13
72	Clinical, Radiological, and Laboratory Features of Spinal Cord Involvement in Primary SjÃ¶grenâ€™s Syndrome. Journal of Clinical Medicine, 2020, 9, 1482.	2.4	13

#	Article	IF	Citations
73	The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective. Brain, 2022, 145, 426-440.	7.6	13
74	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 21-28.	2.3	12
75	Innovative therapeutic concepts of progressive multifocal leukoencephalopathy. Journal of Neurology, 2022, 269, 2403-2413.	3.6	12
76	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2019, 86, 322-324.	5.3	11
77	Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. Journal of Affective Disorders, 2015, 185, 144-148.	4.1	10
78	Validation of an MRI Rating Scale for Amyloidâ€Related Imaging Abnormalities. Journal of Neuroimaging, 2017, 27, 318-325.	2.0	10
79	Exploring resting state connectivity in patients with psychotic depression. PLoS ONE, 2019, 14, e0209908.	2.5	10
80	Single-subject structural cortical networks in clinically isolated syndrome. Multiple Sclerosis Journal, 2020, 26, 1392-1401.	3.0	10
81	Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Multiple Sclerosis Journal, 2017, 23, 995-999.	3.0	9
82	Towards a standard MRI protocol for multiple sclerosis across the UK. British Journal of Radiology, 2019, 92, 20180926.	2.2	9
83	Gadolinium should always be used to assess disease activity in MS â€“ No. Multiple Sclerosis Journal, 2020, 26, 767-769.	3.0	9
84	Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 177-188.	1.9	9
85	Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients. Multiple Sclerosis and Related Disorders, 2021, 50, 102838.	2.0	9
86	PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199368.	3.5	9
87	Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurological Research and Practice, 2022, 4, 1.	2.0	9
88	Guidelines on PML risk stratification and diagnosis in patients with MS treated with natalizumab: so far so good?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 87, jnnp-2015-311386.	1.9	8
89	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimerâ€™s patients: An interobserver study. European Radiology, 2018, 28, 1215-1226.	4.5	8
90	Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e483.	6.0	6

#	Article	IF	Citations
91	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. Journal of Oncology, 2020, 2020, 1-9.	1.3	6
92	Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation. Scientific Reports, 2021, 11, 8527.	3.3	6
93	Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry. Journal of Neural Transmission, 2021, 128, 735-747.	2.8	6
94	Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. European Radiology, 2012, 22, 2304-2306.	4.5	5
95	In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?. Multiple Sclerosis Journal, 2017, 23, 1169-1171.	3.0	5
96	Quantitative Imaging in Muscle Diseases with Focus on Non-proton MRI and Other Advanced MRI Techniques. Seminars in Musculoskeletal Radiology, 2020, 24, 402-412.	0.7	4
97	Brain and Spinal Cord MRI in Multiple Sclerosis: an Update. Neurology International Open, 2017, 01, E294-E306.	0.4	3
98	Imaging of meningeal inflammation should become part of the routine MRI protocol â€“ No. Multiple Sclerosis Journal, 2019, 25, 331-333.	3.0	3
99	Application of â€œMentzerâ€™s PML case definitionâ€•to natalizumab-treated patients in the setting of strict MRI-based pharmacovigilance. Journal of Neurology, 2020, 267, 2599-2602.	3.6	3
100	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. NeuroImage: Clinical, 2021, 30, 102659.	2.7	3
101	Analysis of deep grey nuclei susceptibility in early childhood: a quantitative susceptibility mapping and R2* study at 3 Tesla. Neuroradiology, 2022, 64, 1021-1031.	2.2	3
102	Low JC virus antibody index during natalizumab treatment less safe than assumed?. Multiple Sclerosis Journal, 2015, 21, 1753-1754.	3.0	2
103	Neuromyelitis optica spectrum disorder mimicking multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 54-56.	2.0	2
104	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. Journal of Neurology, 2020, 267, 3287-3291.	3.6	2
105	The potential role of diffusion weighted imaging in the diagnosis of early carotid and vertebral artery dissection. Neuroradiology, 2022, 64, 1135-1144.	2.2	2
106	Left atrial myxoma presenting with white matter lesions suggestive of multiple sclerosis: The differential diagnosis goes beyond MRI. Multiple Sclerosis Journal, 2015, 21, 255-255.	3.0	1
107	PS9 - 5. Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds and decreased skin capillary density. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 169-169.	0.0	0
108	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0

#	Article	IF	Citations
109	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0
110	[P1â€“400]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOIDâ€RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIAâ€E) IN PATIENTS AFFECTED BY ALZHEIMER's DISEASE RECEIVING IMMUNOTHERAPY: AN INTERâ€OBSERVER STUDY. Alzheimer's and Dementia, 2017, 13, P425.	0.8	0
111	[F1â€“03â€“04]: BIOMARKERâ€BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.8	0
112	Venoplasty in MS. Neurology, 2018, 91, 815-816.	1.1	0
113	The reality of multiple sclerosis assessment in middle-income countries â€“ Authors' reply. Lancet Neurology, The, 2022, 21, 215-216.	10.2	0